KLOW Blend (80mg)

BPC-157 came out of gastric-juice research at the University of Zagreb in the 1990s. It's a synthetic 15-amino-acid fragment built from a longer gastroprotective protein, and it shows up mostly in tissue-repair, angiogenesis, and gut-mucosal-protection studies in animal models.^[1]

TB-500 is a name, not a peptide sequence in its own right. Mass spectrometry traced the material sold under that name to the N-terminal acetylated 17-23 fragment of thymosin beta-4, a short stretch cut from a much larger 4,963-dalton protein.^[2] Researchers use it in actin-regulation and cell-migration work. The full-length protein and the fragment aren't interchangeable, and older thymosin beta-4 literature doesn't automatically carry over to TB-500.

GHK-Cu is older than either of those. Loren Pickart identified the copper-binding tripeptide, glycyl-L-histidyl-L-lysine, in human plasma in 1973, while comparing blood from younger and older donors. Decades of follow-up work since then tie it to gene-expression changes around collagen synthesis, antioxidant activity, and wound healing.^[3]

KPV is the smallest of the four: three amino acids, Lys-Pro-Val, clipped from the tail end of alpha-melanocyte-stimulating hormone. Strip away the rest of alpha-MSH and the pigmentation signaling goes with it, but KPV keeps showing anti-inflammatory activity on its own, including in intestinal-inflammation models.^[4]

One purity number doesn't cut it here. A four-component blend needs four confirmed identities on the same Certificate of Analysis, one per peak: BPC-157, TB-500, GHK-Cu, and KPV. Tetrava Labs publishes that lot-linked HPLC-MS data in the COA library, so you can check the batch against what's actually in your hands before starting comparative work.

The FDA put BPC-157 and the thymosin beta-4 fragment sold as TB-500 on its Category 2 list of significant-safety-risk bulk substances back in 2023.^[5] Both stayed Research Use Only after that. GHK-Cu and KPV never landed on that list, for what it's worth, but the finished blend still ships under the same RUO restriction. Regulatory history on one ingredient doesn't change how the other three get treated.

Buying four peptides from four separate vials means four identity checks and four chances for lot variation to creep in. A fixed-ratio blend collapses that into one lot, one COA, one set of numbers to trust.

Each of the four sits in its own pathway: tissue-repair signaling for BPC-157, actin regulation for TB-500, copper-peptide gene modulation for GHK-Cu, cytokine-linked anti-inflammatory signaling for KPV. A lab running a comparative protocol, blend against single components, or KLOW against the three-peptide GLOW Blend, can isolate exactly what adding KPV changes in a given assay.

GLOW and KLOW start the same: BPC-157, TB-500, GHK-Cu. KLOW just keeps going and adds KPV. Run both blends side by side and you're really testing one variable, whether the anti-inflammatory tripeptide shifts the result against the three-peptide baseline, not comparing two unrelated products.

The fastest way to confirm that difference isn't the label. It's the chromatogram. GLOW resolves three peaks. KLOW resolves four, and that fourth peak needs to match KPV on both mass and retention time. Whatever the marketing name says, the COA is the only thing that actually tells you what's in the vial.

KLOW Blend ships lyophilized, which is what keeps it stable in transit. Keep sealed vials at -20°C, skip the freeze-thaw cycles, and reconstitute right before use under sterile technique with whatever diluent your protocol calls for.

Once it's reconstituted, hold it at 4°C and use it inside the window your lab's SOP sets for a multi-peptide prep. Write down the diluent lot, the date, the target concentration, and who did it. That's what keeps a four-component identity auditable against the batch Certificate of Analysis later. None of this is dosing advice. It's lab prep, for people running the assay, not for anyone administering it to themselves or anyone else.